Latest News and Press Releases

The company continues to focus on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the...

PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...

Promotes Carol Smith, Ph.D., to Manager of Quality as Part of Manufacturing Optimization Retains Step Change Pharma as Advisor to Strengthen Manufacturing and Technical Infrastructure Retains...

PHILADELPHIA, July 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) ("Hemispherx" or the “Company") today announced key elements of its strategic growth plan as well as additional...

PHILADELPHIA, July 11, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) in response to various questions about the status of the work to repair damage to our Alferon®...

PHILADELPHIA, June 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) is pleased to announce that it has entered into multiple agreements and stipulations to settle all material...

PHILADELPHIA, June 07, 2016 (GLOBE NEWSWIRE) -- Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology,...

PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights...

PHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for...

PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...